Thank you to all of you who completed PHCN’s grazoprevir / elbasvir patient input survey and the earlier Technivie patient input survey. Thank you also for sharing them with others. It was truly an honour to read your responses and to use them to write the patient group input report for the Canadian Agency for Drugs and Technologies in Health (CADTH) on your behalf.
The patient group input reports requested by CADTH are an important step towards getting new treatments for hep C more widely available in Canada and BC.
The patient input about grazoprevir / elbasvir was sent in this morning. We now wait to hear the outcome of the treatment submissions.
The Hepatitis C Treatment Information Project will keep you apprised of any news and is here to answer any questions you may have.
Thank you for taking the time to voice your opinion and help advocate for a better tomorrow.
On November 2 @ 11am PST / 1pm EST, the Canadian Treatment Action Council (CTAC) will be hosting a CTAC Patient Input Group Webinar about the exciting new hep C treatment grazoprevir / elbasvir.
The patient input survey that will follow CTAC’s grazoprevir / elbasvir webinar is different from PHCN’s patient input survey or PHCN’s loved ones / caregivers survey. Please consider filling out the PHCN survey that was created for you as well as CTAC’s survey.
Registration for the CTAC webinar is required to attend. Click here to register or for more information about the webinar.
About the Canadian Treatment Action Council (CTAC)
CTAC is a Canadian non-governmental organization led by and for people living with HIV and HIV/HCV co-infection. Since 1996, they have been working to secure and ensure equitable, affordable, and timely access to treatment and care and support for people in Canada living with HIV and HIV/HCV co-infection.